低剂量反应停联合地塞米松治疗多发性骨髓瘤的临床观察

目的：观察低剂量反应停（thalidomide）联合地塞米松治疗多发性骨髓瘤（MM）的疗效。方法：18例MM患者中10例为初治患者、8例为复发难治性患者。反应停初始剂量为50～100 mg.d-1,每周增加50mg,2周后增加到200 mg.d-1;至少每天100 mg/d,服用3-6个月。同时联合地塞米松10mg.d-1,连服4天,每月1次。结果：完全缓解（CR）3例,部分缓解（PR）6例,微缓解（MR）7例,无效2例。无不能耐受的副反应。结论：地剂量反应停联合地塞米松治疗初发和复发难治性多发性骨髓瘤安全有效。

The Clinical Effectiveness Of Low Dose Thalidomide Combined With Dexamethasone On Multiple Myeloma

Objective： To observe the effectiveness of low dose thalidomide combined with dexamethasone（LD-TD） on patients with multiple myeloma（MM）.Methods： 18 cases with MM were enrolled for studies.Among them,10 case are initial treament and 8 cases are relapsed or/and refractory patients.The initial dosage of thalidomide was100 mg·d-1 with a increasing in 50 mg·d-1 weekly and the maximum dosage was 200 mg·d-1.At the same time,the administerd dosage of dexamethasone was 10 mg·d-1 for 4 days every month.Results： Among the 18 evaluable patients,3 of them achieved complete remission（CR）,6 of them achieved partial remission（PR）,7 of them showed partial improving and 2 of them had no effects.Side effects could been tolerate.Conclusion： LD-TD might be effective in these patients with relapsed or/and refractory MM,as well as these patients with initial treatment MM.